A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

1991, Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials, Br. Med. J., 303, 884, 10.1136/bmj.303.6807.884 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 Piccart, 1997, Is cisplatin–paclitaxel (P–T) the standard in the first line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCIC and Scottish Intergroup experience, Proc. Am. Soc. Clin. Oncol., 16, 352a Goetzl, 1996, Matrix metalloproteinases in immunity, J. Immunol., 156, 1, 10.4049/jimmunol.156.1.1 Cawston, 1995, Proteinases and inhibitors, Br. Med. J., 51, 385 De Clerck, 1994, Matrix metalloproteinases and their inhibitors in tumor progression, Ann. N. Y. Acad. Sci., 732, 222, 10.1111/j.1749-6632.1994.tb24738.x Brown, 1995, Matrix metalloproteinase inhibition: a review of anti-tumour activity, Ann. Oncol., 6, 967, 10.1093/oxfordjournals.annonc.a059091 John, 2001, The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis, Pathol. Oncol. Res., 7, 14, 10.1007/BF03032599 Sakata, 2000, Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary, Int. J. Oncol., 17, 673 Davidson, 1999, High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlated with poor survival in ovarian carcinoma, Clin. Exp. Metastasis, 17, 799, 10.1023/A:1006723011835 Schmalfeldt, 2001, Increased expression of matrix metalloproteinases MMP-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer, Clin. Cancer Res., 7, 2396 Davidson, 2002, The prognostic value of metalloproteinases and angiogenic factors in ovarian cancer, Mol. Cell. Endocrinol., 187, 39, 10.1016/S0303-7207(01)00709-2 Murphy, 1994, Regulation of matrix metalloproteinase activity, Ann. N. Y. Acad. Sci., 732, 31, 10.1111/j.1749-6632.1994.tb24722.x Levy, 1997, Matrix metalloproteinase inhibiting drugs, Emerg. Drugs, 2, 205, 10.1517/14728214.2.1.205 Kluender H, Dixon B, VanZandt M. et al. Substituted 4-biarylbutyric acid derivatives as matrix metalloproteinase inhibitors. U.S. patent 5,861,428 granted to Bayer Corp. January 19, 1999. Rowinsky, 2000, Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies, J. Clin. Oncol., 18, 178, 10.1200/JCO.2000.18.1.178 Grochow, 1998, Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566, Proc. Am. Soc. Clin. Oncol., 17, 213a Erlichman, 1998, Phase I study of BAY 12-9566—a matrix metalloproteinase inhibitor (MMPI), Proc. Am. Soc. Clin. Oncol., 17, 217a Hirte, 2000, A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours, Ann. Oncol., 11, 1579, 10.1023/A:1008347630465 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Duivenvoorden, 2001, Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study, Int. J. Cancer, 15, 857, 10.1002/1097-0215(200002)9999:9999<::AID-IJC1135>3.0.CO;2-M Moore, 2000, A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer, Proc. Am. Soc. Clin. Oncol., 19, 240a Grochow, 1998, Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors (MMPIs), Ann. Oncol., 9, 75 Neri, 1998, Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor AG3340 in single agent and combination therapy against B16–F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proc. Am. Assoc. Cancer Res., 39, 302 Wojtowicz-Praga, 1998, Phase I trial of marismastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer, J. Clin. Oncol., 16, 2150, 10.1200/JCO.1998.16.6.2150 Hande, 1998, A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer, Ann. Oncol., 9, 74 Krane, 1994, Clinical importance of metalloproteinase and their inhibitors, Ann. N. Y. Acad. Sci., 732, 1, 10.1111/j.1749-6632.1994.tb24719.x Bramhall, 2001, Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial, J. Clin. Oncol., 19, 3447, 10.1200/JCO.2001.19.15.3447 Bramhall, 2002, Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial, Br. J. Cancer, 86, 1864, 10.1038/sj.bjc.6600310 Shepherd, 2001, Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC Study, Proc. Am. Soc. Clin. Oncol., 20, 11a Wagenaar-Miller, 2004, Matrix metalloproteinases in colorectal cancer: is it worth talking about?, Cancer Metastasis Rev., 23, 119, 10.1023/A:1025819214508 Markman, 2003, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial, J. Clin. Oncol., 21, 2460, 10.1200/JCO.2003.07.013 Douillard, 2001, Randomized phase II study of BMS-275291 versus placebo in patients with stage IIIB or IV non-small cell lung cancer receiving paclitaxel plus carboplatin. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.18, Eur. J. Cancer, 37, S19, 10.1016/S0959-8049(01)80555-4